E2F3 is overexpressed in 55-70% of squamous cell carcinomas and 79% of adenocarcinomas of the lung. In addition very high level expression of nuclear E2F3 is found in almost all small cell lung cancers analysed.

Our results suggest that down-regulation of miR-200b could lead to E2F3 overexpression and in turn contribute to chemoresistance of lung adenocarcinoma cells to docetaxel.

Studies revealed that E2F3 was a direct target of miR-449a in lung cancer cells. miR-449a also suppressed tumor formation in vivo in nude mice. These results suggest that miR-449a plays an important role in lung cancer tumorigenesis.

novel HDAC1/4/miR-200b/E2F3 signaling contributes to chemoresistance of human lung adenocarcinoma cells

HLM006474 synergizes with paclitaxel in lung cancer cell lines to inhibit E2F

High expression level of E2F3 is associated with lung adenocarcinoma.

NEAT1 modulated the expression of E2F3 and MiR377 and promoted non small cell lung cancer progression.

Blood E2F3 mRNA is a sensitive diagnostic marker in lung cancer; moreover, it is a promising prognostic marker capable of efficiently discriminating early from late stages of the disease

miR433 may inhibit the progression of nonsmallcell lung cancer, at least in part, by targeting E2F3. The present study indicated that miR433 may be investigated as an innovative candidate target for the therapy of patients with this fatal disease.